Susquehanna International Group
HEPA

Susquehanna International Group’s Hepion Pharmaceuticals HEPA Stock Holding History

Susquehanna International Group’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-37
Closed -$28.9K – 12499
2023
Q1 		$28.9K Sell
37
-20
-35% -$14.8K ﹤0.01% 11928
2022
Q4 		$17.1K Buy
57
+3
+6% +$1.27K ﹤0.01% 11810
2022
Q3 		$28K Sell
54
-35
-39% -$21.4K ﹤0.01% 12469
2022
Q2 		$51K Sell
89
-128
-59% -$107K ﹤0.01% 11963
2022
Q1 		$280K Buy
217
+83
+62% +$91.7K ﹤0.01% 10435
2021
Q4 		$153K Sell
134
-308
-70% -$422K ﹤0.01% 11763
2021
Q3 		$677K Buy
442
+264
+148% +$423K ﹤0.01% 8615
2021
Q2 		$351K Sell
178
-177
-50% -$324K ﹤0.01% 10427
2021
Q1 		$652K Buy
355
+247
+229% +$541K ﹤0.01% 8846
2020
Q4 		$237K Buy
108
+90
+500% +$233K ﹤0.01% 9751
2020
Q3 		$54K Buy
+18
New +$64.6K ﹤0.01% 10181

Other funds holding HEPA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's HEPA Position: Q1 2025 in Review

Susquehanna International Group sold out of Hepion Pharmaceuticals (HEPA) in Q1 2025, closing a stake of 521 shares — an estimated $12.2K sold.

Susquehanna International Group first reported a position in HEPA in Q2 2019 and held it in 18 quarters. The position peaked at $651K in Q1 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q1 2025.

  • Susquehanna International Group reported no remaining Hepion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 521 Hepion Pharmaceuticals shares in Q1 2025, an estimated $12.2K.
  • Susquehanna International Group first reported a position in Hepion Pharmaceuticals in Q2 2019 and held it in 18 quarters.
  • Susquehanna International Group's Hepion Pharmaceuticals position peaked at $651K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.